Lungs News and Research

RSS

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria.

22 Oct 2008

Aires Pharmaceuticals signs license agreement with NIH

Aires Pharmaceuticals Inc. today announced the signing of an exclusive license agreement with the U.S. National Institutes of Health for the patented use of a nitric oxide prodrug to treat cardiopulmonary conditions.

22 Oct 2008

New TB test more accurate in predicting those most susceptible

Scientists have developed a new blood test which promises to more accurately predict those most likely to develop tuberculosis (TB).

22 Oct 2008

New atlas maps geographical pattern of mortality in Great Britain

Researchers from the Universities of Bristol and Sheffield have created an 'atlas of death' which charts the geographical pattern of mortality in Great Britain. The full-colour atlas shows the wide variation in death rates from a variety of different causes, from heart attacks and cancer to suicide and murder, for over 1,000 neighbourhoods.

20 Oct 2008

Nicotine linked to breast cancer growth and spread

A study published in Cancer Research, a journal of the American Association for Cancer Research, suggests a possible role for nicotine in breast tumor development and metastases.

15 Oct 2008

Qld uni student diagnosed with tuberculosis

A student at the Queensland University of Technology (QUT) in Brisbane has been diagnosed with tuberculosis (TB) and as a result 160 staff and students at the University are being screened for the disease.

14 Oct 2008

Steroids aid recovery from pneumonia, UT Southwestern researchers say

Adding corticosteroids to traditional antimicrobial therapy might help people with pneumonia recover more quickly than with antibiotics alone, UT Southwestern Medical Center scientists have found.

14 Oct 2008

TB Alliance enters into collaboration with sanofi-aventis to fight tuberculosis

The Global Alliance for TB Drug Development (TB Alliance) and sanofi-aventis announced today that they have entered into a collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB). The TB Alliance is a not-for-profit, product development partnership, whose goal is the development of new TB drugs.

14 Oct 2008

OncoGenex achieves key regulatory milestone for lead product candidate

OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).

13 Oct 2008

Preventing lung disease in indigenous communities

A pilot health initiative partly developed at the University of Sydney could significantly reduce the debilitating impact of chronic lung disease within indigenous communities.

13 Oct 2008

Link found between mitochondria and tumor formation in stem cells

Researchers report on a previously unknown relationship between stem cell potency and the metabolic rate of their mitochondria -a cell's energy makers. Stem cells with more active mitochondria also have a greater capacity to differentiate and are more likely to form tumors.

12 Oct 2008

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis

Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.

12 Oct 2008

Children with cystic fibrosis not well covered by guidelines for vitamin D needs

Existing recommendations for treating vitamin D deficiency in children with cystic fibrosis (CF) are too low to cover the serious need, leaving most at high risk for bone loss and rickets, according to researchers at Johns Hopkins Children's Center.

12 Oct 2008

Red wine cuts smokers risk for lung cancer

Cancer experts say drinking red wine may decrease the risk of lung cancer in men who smoke, because of its antioxidant properties.

7 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008